Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Mergers and Acquisitions

Project details

British Biomedicine R&D firm with new drug against MRSA looking for investors

Project region Britain, United Kingdom
Industry Healthcare
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365

CONTACT ADVISOR

Simon Laube
Assistant Manager, International Business Advisory
Project highlights The market value is 19 million pounds.
Project description

The company has developed a new anti-infection drug with outstanding and rapid bacterial activity against Staphylococcus aureus (SA), which is the biggest cause of nosocomial bacterial infection in the world. The leading drug has completed clinical trials funded by the US government. Different from traditional antibiotics, this drug shows excellent resistance to SA bacteria in the laboratory where it has produced a series of low bacterial resistance potentials, and can be used to prevent and treat MRSA infection. The company has been listed on the Alternative Investment Market (AIM), a sub-market of London Stock Exchange (LSE), with a market value of 19 million pounds.

Get in touch

We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.

Have Any Questions?

Reach out to our local experts, we’ll respond within one business day.

captcha image

Our Clients

Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.

See what our clients say about us

It appears that you have recently submitted an inquiry on this topic. Would you like to
replace your previous submission with this one?